Starting empagliflozin in people on insulin and with good glycaemic control

Website intended for a NZ health professional readership

+Practice

In print

PHARMACOTHERAPY

Starting empagliflozin in people on insulin and with good glycaemic control

3 March 2021

By Penny Clark and Linda Bryant

Wednesday 3 March 2021, 12:35 AM

Increased blood glucose monitoring is encouraged when starting empagliflozin

Your patient uses gliclazide and insulin but could still benefit from the additional cardiovascular and renal protections of empagliflozin. How would you manage the change in treatment?

Key points, Empagliflozin reduces the renal and cardiovascular complications of type 2 diabetes, even when blood glucose level is well controlled. Empagliflozi, Pract Green w Pale Yellow

Medicines and Therapies

References

Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2012;372:m4573.
Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 2015;373(22):2117–28.

How to Treat

+How to treat

Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality

Wednesday 29 January 2025, 12:45 AM